A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Trial Details

NCT ID
NCT06695845
Phase
PHASE2
Sponsor
Jazz Pharmaceuticals
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Zanidatamab
Locations (sample)
  • Prescott, Arizona, United States|34.54002,-112.4685
  • Littleton, Colorado, United States|39.61332,-105.01665
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Orlando, Florida, United States|28.53834,-81.37924
  • St. Petersburg, Florida, United States|27.77086,-82.67927

Key Eligibility Criteria

  • Is at least 18 years of age inclusive at the time of signing the informed consent
  • Participants with locally advanced, unresectable, or metastatic solid tumors (except Biliary Tract Cancer (BTC), defined as gallbladder cancer or c…
  • HER2 overexpression (IHC 3+) must be determined by a sponsor designated central laboratory.
  • All participants must have adequate tumor sample for submission to allow central HER2 testing.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →